Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Aung Naing, David S. Hong et al.|Cancer|2023Cited by 17